Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Oncology Focused On Combinations, But Differentiation Will Be Key

Executive Summary

AstraZeneca is in the midst of a concerted push in oncology, but many of its top contenders are in crowded classes. The firm sees its future in the possibilities of combinations with immunotherapies.

You may also be interested in...



AstraZeneca Immuno-Oncology Hopes Buoyed By Tremelimumab

Quick path to lung cancer approval may not happen for durvalumab, but AstraZeneca could make its immuno-oncology debut with first CTLA-4/PD-L1 combination. Outlook in nephrology is also looking good, firm says at pipeline review.

Eisai’s Lenvima Will Face Off Against Nexavar In Thyroid Cancer

Approved two months early, tyrosine kinase inhibitor’s labeling reflects 14.7-month progression-free survival improvement in patients with differentiated thyroid cancer, almost triple the benefit seen with Bayer/Amgen’s sorafenib.

With Oncology Drugs On The Way, AstraZeneca Sets The Stage For New Launches

U.S. President Paul Hudson says AstraZeneca is building specialty commercial team ahead of new oncology launches; MedImmune seals new deals in its quest for winning combinations in immuno-oncology.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS055416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel